CD8A and cancer: mRNA-lipid nanoparticle (LNP) vaccines targeting somatic mutation-derived neoantigens have demonstrated the capacity to generate long-lived CD8+ T cells in pancreatic ductal adenocarcinoma (PDAC) patients, overcoming a major obstacle in cancer vaccinology by producing long-lived and functional specific-T cells (63).